期刊文献+

剪切波弹性成像与血清肝纤维化指标无创评估慢性乙型肝炎患者肝纤维化效能比较 被引量:14

Comparison of the efficacy between shear wave elastrography and serum fibrosis indexes in non-invasive evaluation of hepatic fibrosis in chronic hepatitis B patients
下载PDF
导出
摘要 目的比较剪切波弹性成像(SWE)与血清学纤维化指标无创评价慢性乙型肝炎(CHB)患者肝纤维化的效能。方法 2018年1月至2020年3月淮安市第四人民医院收治CHB患者74例。应用Scheuer评分系统进行肝纤维化分级,定义S0、S1期为非显著肝纤维化(非显著组),S2、S3及S4期为显著肝纤维化(显著组)。计量资料行t检验,计数资料行卡方检验。Logistic回归分析CHB患者显著肝纤维化的独立预测因素。构建SWV及血清学纤维化指标诊断CHB患者显著肝纤维化的ROC曲线,计算曲线下面积(AUC)、敏感度及特异度,取约登指数最大处为各指标诊断时的截断点。结果 CHB肝纤维化S0期7例,S1期18例,S2期27例,S3期11例,S4期11例。非显著组年龄为(37.2±6.0)岁,低于显著组的(42.9±9.6)岁,差异有统计学意义(P<0.05)。非显著组患者ALT、ALP、GGT、总胆固醇、PLT、RDW及INR分别为(42.4±7.9)U/L、(102.4±22.2)U/L、(42.3±11.4)U/L、(3.8±1.0)mg/dL、(182.6±40.8)×10^(9)/L、(13.8±0.9)%及(1.0±0.2),显著纤维化组分别为(58.3±18.2)U/L、(131.5±28.5)U/L、(80.2±16.3)U/L、(5.5±1.4)mg/dL、(92.4±32.4)×10^(9)/L、(11.6±1.8)%及(1.2±0.3),差异均有统计学意义(P<0.05)。非显著组SWV为(1.44±0.22)m/s,低于显著组(1.92±0.38)m/s,差异均有统计学意义(P<0.05)。非显著组患者血清学纤维化指标HA、C-IV、APRI、FIB-4、Forns评分及RPR分别为(70.2±12.6)ng/mL、(63.4±21.5)ng/mL、(0.3±0.2)、(0.8±0.3)、(-0.6±0.5)分及(0.08±0.02),显著纤维化组分别为(55.9±30.8)ng/mL、(42.8±18.9)ng/mL、(0.7±0.5)、(1.3±0.4)、(0.4±0.8)分及(0.11±0.02),差异均有统计学意义(P<0.05)。多因素Logistic回归分析结果显示,GGT、HA、C-IV、PLT、SWV、FIB-4、APRI、FIB-4、Forns评分及RPR为影响显著肝纤维化的独立预测因素。SWE诊断肝纤维化的AUC值为0.86,高于APRI、FIB-4、Forns评分、FobroIndex、RPR的0.74、070、0.74和0.69。结论 SWE是一种可靠的无创性评估CHB患者肝纤维化的方法,其诊断性能优于APRI、FIB-4、Forns评分及RPR等血清学纤维化指标。 Objective To compare the efficacy between shear wave elastrography(SWE)and serological fibrosis markers in non-invasive evaluation of hepatic fibrosis in patients with chronic hepatitis B(CHB).Methods 74 patients(44 males and 30 females)with CHB were admitted to our hospital from January 2018 to March 2020,with an average age of(40.2±7.8)years.The measurement data were analyzed by t-test and the counting data were analyzed by chi-square test.Univariate and multivariate Logistic regression analysis were performed to determine the independent predictors of significant liver fibrosis in patients with CHB.To construct the Receiver operating characteristic(ROC)curve of shear wave velocity(SWV)and serological fibrosis indexes for diagnosing significant hepatic fibrosis in patients with CHB.The area under the curve(AUC),sensitivity and specificity were calculated.The maximum Jordan index was taken as the cutoff point for each diagnostic index.Results Hepatic fibrosis was graded by Scheuer score system.S0 and S1 stages were defined as non-significant hepatic fibrosis(non-significant fibrotic group),and S2,S3 and S4 stages were defined as significant hepatic fibrosis(significant fibrotic group).Among 74 CHB patients,7 cases were in S0 stage of liver fibrosis,18 cases were in S1 stage,27 cases were in S2 stage,11 cases in S3 stage and 11 cases in S4 stage.The average age of the non-significant fibrotic group was(37.2±6.0)years,which was younger than that of the significant fibrotic group[(42.9±9.6)years,P<0.05].The levels of ALT,ALP,GGT,total cholesterol,PLT,RDW and INR in the non-significant fibrotic group were(42.4±7.9)U/L,(102.4±22.2)U/L,(42.3±11.4)U/L,(3.8±1.0)mg/dL,(182.6±40.8)×10^(9)/L,(13.8±0.9)% and(1.0±0.2),respectively,which were significantly different with those of the control group[58.3±18.2)U/L,(131.5±28.5)U/L,(80.2±16.3)U/L,(5.5±1.4)mg/dL,(92.4±32.4)×10^(9)/L,(11.6±1.8)%and(1.2±0.3)],(P<0.05).The SWV in non-significant fibrotic group was(1.44±0.22)m/s,which was significantly lower than that in the significant fibrotic group[(1.92±0.38)m/s,P<0.05].The serological fibrosis indexes HA,CIV,APRI,FIB-4,Forns score and RPR in the non-significant group were(70.2±12.6)ng/mL,(63.4±21.5)ng/mL,(0.3±0.2),(0.8±0.3),(-0.6±0.5)and(0.08±0.02),respectively,which were significantly different with the control group[(55.9±30.8)ng/ml,(42.8±18.9)ng/mL,(0.7±0.5),(1.3±0.4),(0.4±0.8)and(0.11±0.02)](P<0.05).Multivariate Logistic regression analysis was carried out with the existence of significant liver fibrosis in patients with CHB as dependent variables and the above significant differences as independent variables.GGT,HA,C-IV,PLT,SWV,FIB-4,APRI,FIB-4,Forns score and RPR were independent predictors of significant liver fibrosis.When evaluating significant hepatic fibrosis,the AUC values of SWE were significantly higher than those of APRI,FIB-4,Forns,FibroIndex,RPR,HA and C-IV,respectively.Conclusion SWE is a reliable and non-invasive method for evaluating hepatic fibrosis in patients with CHB.The diagnostic performance of SWE is superior to serological fibrosis indexes such as HA,C-IV,APRI,FIB-4,Forns score and RPR.
作者 张荣荣 周瑾 赵鹏 朱礼尧 张鑫 叶晓航 ZHANG Rong-rong;ZHOU Jing;ZHAO Peng;ZHU Li-yao;ZHANG Xin;YE Xiao-hang(Color Doppler Ultrasound Room of Imaging Department,Huaian Fourth People's Hospital,Jiangsu 223002,China)
出处 《肝脏》 2021年第3期255-258,共4页 Chinese Hepatology
基金 北京医卫健康公益基金资助项目(YWJKJJHKYJJ-Q17023)。
关键词 慢性乙型肝炎 剪切波弹性成像 APRI FIB-4 Chronic hepatitis B Shear wave elastography APRI FIB-4
  • 相关文献

参考文献2

二级参考文献11

  • 1European Association for the Study of the Liver.EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection[J]. Journal of Hepatology . 2012 (1)
  • 2E. Jenny Heathcote,Patrick Marcellin,Maria Buti,Edward Gane,Robert A. De Man,Zahary Krastev,George Germanidis,Samuel S. Lee,Robert Flisiak,Kelly Kaita,Michael Manns,Iskren Kotzev,Konstantin Tchernev,Peter Buggisch,Frank Weilert,Oya Ovunc Kurdas,Mitchell L. Shiffman,Huy Trinh,Selim Gurel,Andrea Snow–Lampart,Katyna Borroto–Esoda,Elsa Mondou,Jane Anderson,Jeff Sorbel,Franck Rousseau.Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B[J]. Gastroenterology . 2011 (1)
  • 3Robert G. Gish,Margaret D. Clark,Steve D. Kane,Richard E. Shaw,Michael F. Mangahas,Sumbella Baqai.Similar Risk of Renal Events Among Patients Treated With Tenofovir or Entecavir for Chronic Hepatitis B[J].Clinical Gastroenterology and Hepatology.2012(8)
  • 4Patrick Marcellin,Edward Gane,Maria Buti,Nezam Afdhal,William Sievert,Ira M Jacobson,Mary Kay Washington,George Germanidis,John F Flaherty,Raul Aguilar Schall,Jeffrey D Bornstein,Kathryn M Kitrinos,G Mani Subramanian,John G McHutchison,E Jenny Heathcote.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study[J].The Lancet.2012
  • 5S.Pol,P.Lampertico.First‐line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real‐life’ settings: from clinical trials to clinical practice[J].Journal of Viral Hepatitis.2012(6)
  • 6Stéphane Chevaliez,Christophe Rodriguez,Jean–Michel Pawlotsky.New Virologic Tools for Management of Chronic Hepatitis B and C[J].Gastroenterology.2012(6)
  • 7Ye Zhang,Jian-Qi Lian,Yu Li,Jie-Pin Wang,Chang-Xing Huang,Xue-Fan Bai,Jiu-Ping Wang.Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine[J].European Journal of Gastroenterology & Hepatology.2013(7)
  • 8Myron J. Tong,Kris V. Kowdley,Calvin Pan,Ke‐Qin Hu,Ting‐Tsung Chang,Kwang‐Hyub Han,Seung‐Kew Yoon,Zachary D. Goodman,Suzanne Beebe,Uchenna Iloeje,Hong Tang.Improvement in liver histology among Asian patients with chronic hepatitis B after long‐term treatment with entecavir[J].Liver Int.2013(4)
  • 9Jorg Petersen,Vlad Ratziu,Maria Buti,Harry L.A. Janssen,Ashley Brown,Pietro Lampertico,Jan Schollmeyer,Fabien Zoulim,Heiner Wedemeyer,Martina Sterneck,Thomas Berg,Christoph Sarrazin,Marc Lutgehetmann,Peter Buggisch.Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study[J].Journal of Hepatology.2011(3)
  • 10C.‐C.Chen,P.‐C.Wang,H.‐W.Chang,C.‐F.Chen.Safety and efficacy of two‐step peginterferon α‐2a treatment in patients of chronic hepatitis B with acute exacerbation[J].Journal of Viral Hepatitis.2012(3)

共引文献27

同被引文献149

引证文献14

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部